Neohemodesum - instructions for use, dose, side effects, contraindications

The effect of the drug is due to the ability of low molecular weight polyvinylpyrrolidone (povidone-8 thousand) to bind toxins circulating in the blood and quickly remove them from the body. The most fully binds toxins circulating in the blood of patients with toxic dysentery and dyspepsia, sepsis, salmonellosis, food poisoning.

In case of burn disease, toxins formed in the first 4-5 days of the disease are almost completely inactivated; toxins formed at a later date are much less neutralized.

Toxins formed in the body of patients with acute radiation sickness do not bind, although it is possible to accelerate their excretion from the body. The drug contributes to the elimination of stasis of erythrocytes in capillaries, developing with intoxication of any origin,which leads to an improvement in microcirculation. It enhances kidney blood flow, increases glomerular filtration and increases diuresis.

The drug is low-toxic, does not possess antigenic and pyrogenic properties. Reduced molecular weight of the polymer accelerates excretion of the kidney from the body and improves the detoxification properties of the drug.

Pharmacokinetics:

Low molecular weight polyvinylpyrrolidone (povidone-8 thousand) is not metabolized in the body. Quickly excreted by the kidneys, within 4 hours - 80%, after 12-24 h - completely.

Indications:

As a detoxification drug (LS): toxic forms of diseases of the gastrointestinal tract (GIT) (including shigellosis, salmonellosis, dyspepsia); peritonitis, intestinal obstruction (in the pre- or postoperative period); sepsis; Burn disease in the septicopiaemia stage, exogenous poisoning in the stage of toxemia.

Contraindications:

Hypersensitivity, intracranial hypertension, hemorrhagic stroke, condition after craniocerebral trauma (CCI), chronic heart failure (CHF) IIb-III st., Respiratory failure, severe allergic reactions, thromboembolism, oliguria, anuria, acute nephritis, bronchial asthma, phlebothrombosis .

Pregnancy and lactation:

During pregnancy, the drug is used if the benefit to the mother exceeds the possible risk to the fetus.

During the use of the drug, breastfeeding should be discontinued.

Dosing and Administration:

Intravenously (intravenously) drip (40-80 cap / min).

The dose depends on the age of the patient and the severity of the intoxication.

Single dose for adults and children over 15 years of age - 200-500 ml; for children - 2.5 ml / kg.

The maximum single dose for infants is 70 ml, 2-5 years - 100 ml, 6-9 years -150 ml, 10-15 years - 200 ml. Enter 1-2 times a day for 1-10 days.

Side effects:

- Reduction of blood pressure (BP), tachycardia, difficulty breathing, redness of the skin (with rapid administration);

- allergic reactions of varying severity (up to the development of anaphylactic shock);

- infection at the injection site, thrombosis or phlebitis, spreading from the site of infusion.

Overdose:

Symptoms of overdose (with rapid introduction): a decrease in blood pressure, tachycardia, the appearance of a feeling of difficulty breathing, violation of electrolytic balance.

Symptomatic therapy.

Interaction:

There are no data on drug interaction of the drug.

Special instructions:

With extensive burns combined with the introduction of plasma, albumin, gamma globulin.

Before the start of the infusion, it is necessary to check the expiry date of the package. The drug should be clear, free of sediment, sediment and mold. Pressing the container with the preparation is checked for its tightness and the integrity of the package. The results of visual inspection are recorded in the medical history.

Before administration, the solution is warmed to body temperature.

During the treatment, it is necessary to monitor blood pressure and the patient's condition.

Effect on the ability to drive transp. cf. and fur:Data on the effect of the drug on the ability to drive vehicles and maintain machines and mechanisms that require concentration of attention, no.

Form release / dosage:

Solution for infusions of 200, 250, 400, 500 ml.

Packaging:

The containers are polymeric. Containers with the preparation are packed:

- in two plastic bags (inner and outer bags);

- in a polyethylene (inner) bag and 1, 2, 3, 4, 5 pieces per package of a combined multi-layer film based on aluminum foil (outer package);

-to 1, 2, 3, 4, 5 pieces in a package of combined multi-layer film based on aluminum foil (outer package).

Instructions for medical use are included:

- in the outer package - when packing the container with the solution in plastic bags;

- in transport packaging - when packaging the container with a solution in an outer bag of a combined multilayer film based on aluminum foil, in an amount corresponding to the number of containers with a solution.

Storage conditions:

In a dry, protected from light place at a temperature of 5 to 25 ° C. Keep out of the reach of children

Shelf life:

2 years - when using outer bags of polyethylene film;

2,5 years - when using outer bags of the material of a combined multilayer on the basis of aluminum foil. The preparation should be used until the date indicated on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N003499 / 01

Date of registration:15.12.2008 / 25.06.2010

Expiration Date:Unlimited

The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia

Manufacturer: & nbsp

SYNTHESIS, OJSC Russia

Information update date: & nbsp19.06.2018

Illustrated instructions

Instructions

Neohemodes (Neohaemodes)